Company profile

Ticker
AMGN
Exchange
Website
CEO
Robert A. Bradway
Employees
Incorporated in
Location
Fiscal year end
Former names
AMGEN
SEC CIK
IRS number
953540776

AMGN stock data

(
)
FINRA relative short interest over last month (20 trading days) ?

Calendar

13 Feb 20
26 Feb 20
31 Dec 20

News

Company financial data Financial data

Quarter (USD) Dec 19 Sep 19 Jun 19 Mar 19
Revenue 6.2B 5.74B 5.87B 5.56B
Net income 1.7B 1.97B 2.18B 1.99B
Diluted EPS 2.85 3.27 3.57 3.18
Net profit margin 27.48% 34.30% 37.11% 35.85%
Operating income 2.05B 2.48B 2.68B 2.47B
Net change in cash 51M -15M -8M 69M
Cash on hand 677M 626M 641M 649M
Cost of revenue 1.25B 1.04B 1.01B 1.06B
Annual (USD) Dec 19 Dec 18 Dec 17 Dec 16
Revenue 23.36B 23.75B 22.85B 22.99B
Net income 7.84B 8.39B 1.98B 7.72B
Diluted EPS 12.88 12.62 2.69 10.24
Net profit margin 33.57% 35.35% 8.66% 33.59%
Operating income 9.67B 10.26B 9.97B 9.79B
Net change in cash 97M 71M 51M 52M
Cash on hand 677M 580M 509M 458M
Cost of revenue 4.36B 4.1B 4.07B 4.16B

Financial data from Amgen earnings reports

81.5% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 2015 1849 +9.0%
Opened positions 275 126 +118.3%
Closed positions 109 101 +7.9%
Increased positions 650 707 -8.1%
Reduced positions 814 763 +6.7%
13F shares
Current Prev Q Change
Total value 139.84B 88.06B +58.8%
Total shares 480.71M 454.99M +5.7%
Total puts 6.36M 5.57M +14.3%
Total calls 5.54M 4.6M +20.3%
Total put/call ratio 1.1 1.2 -5.0%
Largest owners
Shares Value Change
Vanguard 48.47M $11.69B +0.3%
BLK BlackRock 46.26M $11.15B +0.5%
Capital Research Global Investors 35.34M $8.52B +5.2%
Wealth Quarterback 31.16M $31.16B NEW
STT State Street 26.23M $6.32B +0.9%
FMR 24.49M $5.9B +0.4%
Primecap Management 18.3M $4.41B +0.5%
Geode Capital Management 10.03M $2.41B +1.0%
NTRS Northern Trust 8.03M $1.93B -7.5%
BAC Bank of America 7.54M $1.82B +0.9%
Largest transactions
Shares Bought/sold Change
Wealth Quarterback 31.16M +31.16M NEW
IVZ Invesco 1.65M -5.51M -77.0%
JPM JPMorgan Chase & Co. 3.32M +2.05M +162.3%
Capital Research Global Investors 35.34M +1.74M +5.2%
Winslow Capital Management 1.52M +1.52M NEW
Nuveen Asset Management 4.2M -1.28M -23.4%
Aristotle Capital Management 3.81M +1.27M +50.0%
Johanson Financial Advisors 1.22M +1.21M +24240.9%
Ruffer 11.56K -991.19K -98.8%
D. E. Shaw & Co. 262.16K -980.76K -78.9%

Financial report summary

?
Management Discussion
  • Future sales of our products will depend in part on the factors discussed in the Overview, Part I, Item 1. Business—Marketing, Distribution and Selected Marketed Products—Competition, in Part I, Item 1A. Risk Factors, and any additional factors discussed in the individual product sections below. In addition, for a list of our products’ significant competitors, see Part I, Item 1. Business—Marketing, Distribution and Selected Marketed Products—Competition.
  • The increase in ENBREL sales for 2019 was driven primarily by favorable impacts from changes in accounting estimates of sales deductions and an increase in net selling price, offset partially by lower unit demand. For 2020, we expect the trend of lower unit demand to continue.
  • The decrease in ENBREL sales for 2018 was driven primarily by lower unit demand and net selling price.
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: AB, accuracy, ACME, advice, Alder, analytical, anniversary, Annora, anticompetitive, apremilast, atypical, autoinjector, AVSOLATM, backup, BAFF, Behcet, BeiGene, BioPharma, blocker, Blue, Brexit, bundled, buyer, CANDOR, Canyon, Castillo, celebrate, Celgene, Cesar, CGRP, chosen, Cleveland, cloud, cofounder, complement, comprised, conjugate, consortium, contemplate, contractile, contrast, convenience, costimulatory, Council, cured, curently, curiae, DARZALEX, deposit, disconnect, DOJ, door, downstream, DRL, eculizumab, ejection, embedded, eptinezumab, estate, evidentiary, exploring, EY, fast, formatted, fraction, Fraternal, gastric, GDPR, genital, Glenmark, griffith, hemoglobinuria, hemolytic, HFrEF, HHS, highest, HMO, homolog, immunogenicity, implicit, improperly, Indemnity, inflation, Inline, insufficient, insulin, interact, interactive, interval, intervenor, intervention, invention, Irrevocable, judgement, Kashiv, Kinney, Kirsten, KPH, lending, library, Lodge, lone, lookback, lymphocyte, lymphocytic, Maine, male, Mankind, Mayor, MDL, Miami, misrepresentation, MN, Momenta, MRD, MSP, multidistrict, mutation, myotrope, NaN, nearest, negligent, newest, nocturnal, NSCLC, nuclear, Nuevolution, obstructive, Officerand, oncogene, opposed, Orange, Otezla, otezla®, outage, overnight, overpaid, oversaw, overturned, overturning, panel, paroxysmal, path, payor, penalize, perspective, peter, petitioner, Pharmascience, phosphodiesterase, Pipe, platform, play, PNH, preemptive, preferential, preliminarily, prespecified, presumptively, Prinston, proceeding, prolonged, pulmonary, rat, real, refine, reply, rescheduled, restraining, revert, role, Rozibafusp, Run, Samsung, sarcoma, Scandinavian, sequencing, Sherwood, Shield, Shilpa, Slate, slated, sponte, St, stake, standing, stimulator, stressed, sua, sublease, successor, summer, SureClick, SwissBioSim, tableting, Tanvex, TDAPA, thicket, thrombocytopenia, thrombopoietin, UFCW, unanimously, unconstitutional, Unichem, unopposed, unrest, upholding, uremic, USPTO, vehicle, vendor, viral, waived, Wedbush, workforce
Removed: ABB, accreted, Africa, African, aggregating, agile, attempting, automotive, Barr, BiTE, bortezomib, brand, Brazil, Cambridge, clarifying, compliant, composition, concluding, confronted, construct, coronary, darbepoetin, deadline, debated, declining, deliberately, disclosing, disposed, diversion, Donald, eligibility, ENDEAVOR, erythropoietin, ESPO, exchanged, excluding, exerting, frank, Friedrichshafen, fusion, gave, granting, herringer, improving, inclined, influence, infrastructure, insignificant, Insulet, integration, Lek, lengthen, lifecycle, lift, LUMICEF, Mexico, mid, monotherapy, North, occupy, older, Philadelphia, premium, preserving, prospectively, purifying, qualification, randomized, ranged, reallocate, recombinant, recommending, reinstated, reinvested, reliable, removing, renal, repealing, residential, ROMIPLATE, sBLA, separation, serving, sham, Sherman, sponsor, statute, subset, suspended, switching, TOWER, transformation, Trump, TRW, undistributed, vacated, variation, venture, vertically, withholding, Zealand, ZF